Identifying risk factors for major bleeding in patients with atrial fibrillation using direct oral anticoagulants: a systematic review and meta-analysis

BACKGROUND: Major bleeding (MB) remains a serious complication in atrial fibrillation (AF) patients treated with direct oral anticoagulants (DOACs), but effect estimates for individual factors vary across studies and have not been synthesized in a DOAC-specific framework. OBJECTIVES: To provide a comprehensive DOAC-specific synthesis of risk factors associated with MB in AF patients. METHODS: We systematically searched PubMed, Embase, and the Cochrane Library from their inception to December 2024. We included studies of DOAC-treated AF patients that reported associations between patient characteristics and MB. Random-effects meta-analyses were conducted when at least 2 studies evaluated the same risk factors using comparable definitions. Prespecified subgroup analyses were performed for the MB outcome and for individual DOAC agents. RESULTS: Eighty-three studies involving 970 248 patients were included. Twenty-one variables were associated with MB. We confirmed several well-known risk factors for MB, including a history of bleeding, alcohol use, age ≥65 years, frailty, and high HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (>65 years), and Drugs/alcohol concomitantly) score. Importantly, this DOAC-focused synthesis also highlighted additional and previously underemphasized risk factors, including cancer, myocardial infarction or peripheral artery disease, heart failure, coronary artery disease, and the use of psychotropic or antiarrhythmic drugs. Overweight status and statin use were associated with a lower MB risk, although these findings should be interpreted with caution. CONCLUSION: This meta-analysis provides an integrated, DOAC-specific, quantitative overview of MB risk factors across multiple clinical and treatment domains. The pooled estimates provide a contemporary evidence base to prioritize variables for refinement, recalibration, and validation of MB risk assessment strategies in DOAC-treated AF populations.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Major bleeding (MB) remains a serious complication in atrial fibrillation (AF) patients treated with direct oral anticoagulants (DOACs), but effect estimates for individual factors vary across studies and have not been synthesized in a DOAC-specific framework.

Узнайте, как это исследование связано с клинической практикой

More peer-reviewed studies in Клинические исследования.

• Leech Therapy for Knee Osteoarthritis — The Landmark RCT — Michalsen et al. (2003)
• Leech-Assisted Flap Salvage — Systematic Review of 277 Cases — Whitaker et al. (2012)
• Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
• HIRUDOTHERAPY IN PRESBYACUZIS PRAECOX IN CLEAN-UP WORKERS AFTER THE CHORNOBYL ACCIDENT DURING THE POST-CATASTROPHE YEARS — Zabolotnyi D, Mishchanchuk N (2019)
• Wound healing potential of bark paste of Pongamia pinnata along with hirudotherapy: A case report — Balasooriya D, Karunarathna C, Uluwaduge I (2021)
• AIF-1 and RNASET2 Play Complementary Roles in the Innate Immune Response of Medicinal Leech — Baranzini N et al. (2019)
• Study on the effect of medicinal leech therapy (Hirudo medicinalis) on full-thickness excisional wound healing in the animal model — Zakian A et al. (2022)
• [Hirudo medicinalis-leech applications in plastic and reconstructive microsurgery--a literature review] — Knobloch K et al. (2007)
• The duration of rest and feeding greatly affects the re-breeding of ectoparasites: Hirudo verbana, Hirudo medicinalis and Hirudo orientalis — Aminov R, Frolov A, Aminova A (2022)
• Recombinant hirudin in clinical practice: focus on lepirudin — Greinacher A, Lubenow N (2001)

Browse all ASH-analysed research →